Table 2 Clinical and laboratory characteristics among groups

N

44 (67,6%)

14 (21,5%)

7 (10,7%)

Female

51.2%

42.9%

71.4%

N.S.

Age at baseline (years)

6.7 (4.0–9.2)

8.17 (6.48–9.48)

8.17 (7.4–9.17)

N.S.

Familiar History (Autoimmune disease)

11.4%

7.1%

14.3%

N.S.

TSH (μUI/mL) at baseline

6.6 (6.02–7.35)^a

7.05 (6.07–8.12)

8.2 (6.7–9.4)

0.012

Free thyroxin (ng/dL) at baseline

1.15(1.02–1.3)

1.0(0.95–1.3)

1.0(0.88–1.1)

0.03

TSH (μUI/mL) at follow-up

3.7(2.94–4.27^{)b, c}

6.1(5.17–8.0)^d

1.0(088–1.1)

< 0.001

Free thyroxin (ng/dL) at follow-up

1.07 (0.98–1.2)

1.04(0.9–1.19)

0.88 (0.83–1.1)

N.S.

Percentage change in TSH (baseline vs follow up)

−47.8

((−35.3)-(− 56.7))^b,c

−6.9 ((−17.3)-1.9)^d

24.7 (14.6–95.5)

< 0.001

BMI-SD

−0.61 [(−1.1)-0.83]

0.21 [(− 0.62)-1.18]

0.43[(− 0.68) − 0.85]

NS

Obesity (BMI ≥2 SD)

6 (13,6%)

3 (21,4%)

0 (0%)

N.S.

Height-SD

-0.85 [(− 0.98)-0.67]

−0.45 [(2.27)-0.82]

0.35 [(−2.2)-1.4]

N.S.

Height-SD <2SD

1 (2,2%)

5 (35,7%)

2 (28,5%)

N.S.

TPOAb/TgAb positivity

0 (0%)

0 (0%)

6 (85%)

0.001

Performed US

10 (22%)

6 (42%)

7 (100%)

Tiroiditis by US

0 (0%)

1 (16%)

6 (83%)

0.04